Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma

Clinical Colorectal Cancer

Volumn 7, Issue 1, 2008, Pages 44-47

  Berlin, Jordan D ^a   Venook, Alan ^b   Bergsland, Emily ^b   Rothenberg, Mace ^a   Lockhart, A Craig ^a   Rosen, Lee ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Hematologic toxicity; Neurologic toxicity; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; IRINOTECAN; T 138067; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ACTIVITY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INJECTION SITE PAIN; LEUKOPENIA; MALE; METASTASIS; MICROTUBULE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; TUMOR GROWTH; VISUAL DISORDER;

EID: 39149136517     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.006     Document Type: Article

References (16)

1. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-14.
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7.
3. Shan B, Medina JC, Santha E, et al. Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A 1999; 96:5686-91.
4. Donehower RC, Schwartz GH, Wolff AC, et al. A phase I pharmacokinetic study of T138067 administered as a weekly 3-hour infusion. Proc Am Soc Clin Oncol 2001; 20:110a (Abstract 438).
5. Molpus K, Schwartz G, O'Dwyer P, et al. A phase I study of the anti-microtubule agent T138067-sodium administered daily x5 every 3 weeks. Proc Am Soc Clin Oncol 2002; 21:104a (Abstract 415).
6. Spriggs D, Berg W, Vongprachnach P, et al. A phase I and pharmacology study of the novel antimicrotubule depolymerising agent T138067. Proc Am Soc Clin Oncol 2000; 19:77 (Abstract 921I.)
7. Fleming TR. One-sample multiple testing procedure for phase 2 clinical trials. Biometrics 1982; 38:143-51.
8. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10:239-53.
9. Therasse P, Arbuck SG, Eiseenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-16.
10. Jahan TM, Sandler A, Burris H, et al. A phase II study of T138067-sodium in prior taxanes-treated patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21:321a (Abstract 1282).
11. Leung TW, Feun L, Posey J, et al. A phase II study of T138067-sodium in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2002; 21:144a (Abstract 572).
12. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-40.
13. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-69.
14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2005; 23:3502-8.
15. Giantonio B, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005; 23(16 suppl):1s (Abstract 2).
16. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.